Edwards Lifesciences comments on CMS TAVR national coverage
Edwards Lifesciences issued a statement responding to the CMS national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR).
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.